Clinical meaning
Neuroblastoma is the most common extracranial solid tumor in children and the most common cancer diagnosed during infancy, accounting for approximately 8-10% of all childhood cancers. It arises from primitive neural crest cells, which are embryonic precursor cells that normally differentiate into sympathetic ganglia, adrenal medulla chromaffin cells, and other components of the sympathetic nervous system. During embryogenesis, neural crest cells migrate from the neural tube to populate the sympathetic chain ganglia, adrenal medulla, and paraganglia throughout the body. Malignant transformation of these undifferentiated or partially differentiated neural crest cells produces neuroblastoma. The most common primary site is the adrenal medulla (approximately 40% of cases), followed by the retroperitoneal sympathetic ganglia (25%), posterior mediastinum (15%), pelvis (5%), and neck (5%). The tumor produces and secretes catecholamines (dopamine, norepinephrine, and their metabolites), which are metabolized to vanillylmandelic acid (VMA) and homovanillic acid (HVA). These metabolites can be measured in 24-hour urine collections or spot urine samples and serve as tumor markers for diagnosis and treatment monitoring. Elevated urinary VMA and HVA are found in approximately 90% of neuroblastoma cases, making them highly sensitive screening tools. The biological behavior of neuroblastoma is uniquely variable among human cancers. It spans a spectrum from highly aggressive metastatic disease to spontaneous regression and maturation. Several molecular markers determine prognosis: MYCN oncogene amplification (found in approximately 25% of cases) is the single most important adverse prognostic factor and is associated with rapid tumor progression and poor outcome regardless of age or stage; tumor DNA ploidy (hyperdiploid/near-triploid tumors have a more favorable prognosis than diploid tumors); and segmental chromosomal aberrations (deletions of 1p, 11q, and gain of 17q are associated with aggressive disease). The International Neuroblastoma Staging System (INSS) classifies tumors from Stage 1 (localized, completely resectable) through Stage 4 (distant metastatic disease). A unique category, Stage 4S (special), applies to infants under 12 months of age with localized primary tumor and metastases limited to skin, liver, and bone marrow (less than 10% involvement); Stage 4S tumors have a remarkably favorable prognosis with high rates of spontaneous regression. Opsoclonus-myoclonus syndrome (OMS, also called dancing eyes-dancing feet) is a paraneoplastic condition occurring in approximately 2-4% of neuroblastoma patients, characterized by rapid, involuntary, multidirectional eye movements (opsoclonus), myoclonic jerks of the limbs and trunk, and cerebellar ataxia. Paradoxically, patients with OMS-associated neuroblastoma tend to have more favorable tumor biology but may develop long-term neurological and developmental sequelae. The practical nurse plays a critical role in assessment, family support, chemotherapy safety monitoring, and recognition of oncological emergencies.